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Abstract
Merkel cell polyomavirus (MCV) causes the majority of human Merkel cell carcinomas
(MCC) and encodes a small T (sT) antigen that transforms immortalized rodent fibroblasts
in vitro. To develop a mouse model for MCV sT-induced carcinogenesis, we generated
transgenic mice with a flox-stop-flox MCV sT sequence homologously recombined at the
ROSA locus (ROSAsT), allowing Cre-mediated, conditional MCV sT expression. Standard
tamoxifen (TMX) administration to adult UbcCreERT2; ROSAsTmice, in which Cre is ubiqui-
tously expressed, resulted in MCV sT expression in multiple organs that was uniformly
lethal within 5 days. Conversely, most adult UbcCreERT2; ROSAsTmice survived low-dose
tamoxifen administration but developed ear lobe dermal hyperkeratosis and hypergranulo-
sis. Simultaneous MCV sT expression and conditional homozygous p53 deletion generated
multi-focal, poorly-differentiated, highly anaplastic tumors in the spleens and livers of mice
after 60 days of TMX treatment. Mouse embryonic fibroblasts from these mice induced to
express MCV sT exhibited anchorage-independent cell growth. To examine Merkel cell
pathology, MCV sT expression was also induced during mid-embryogenesis in Merkel cells
of Atoh1CreERT2/+; ROSAsTmice, which lead to significantly increased Merkel cell numbers
in touch domes at late embryonic ages that normalized postnatally. Tamoxifen administra-
tion to adult Atoh1CreERT2/+; ROSAsT and Atoh1CreERT2/+; ROSAsT; p53flox/floxmice had no
effects on Merkel cell numbers and did not induce tumor formation. Taken together, these
results show that MCV sT stimulates progenitor Merkel cell proliferation in embryonic mice
and is a bona fide viral oncoprotein that induces full cancer cell transformation in the p53-
null setting.
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Introduction
Merkel cell polyomavirus (MCV) is clonally integrated into ~80% of Merkel cell carcinomas
(MCC) and is currently the only human polyomavirus known to be oncogenic [1, 2]. This
virus was the first human pathogen discovered by a nondirected RNAseq method called digital
transcriptome subtraction [3], an approach that is now commonly used to discover and charac-
terize human viruses [4]. The MCV T antigen locus encodes two major overlapping transcripts
for the large T (LT) and small T (sT) antigen oncoproteins [5, 6]. All MCV-MCC tumors
examined to date not only carry clonally-integrated virus but also possess clonal tumor-specific
LT mutations that truncate the C-terminus and disrupt the helicase functions of the LT protein
[5, 7, 8]. p53 targeting through a bi-partite interaction domain of the LT antigen of the closely
related Simian vacuolating 40 (SV40) virus is essential for SV40 LT’s transformation activity.
However, no analogous p53 targeting domain has been identified for either MCV LT or sT
oncoproteins [9–11].
MCV sT is a promiscuous E3 ligase inhibitor [12, 13] and alone is sufficient to transform
rodent fibroblast cell lines [14]. MCV sT rodent cell transformation does not require active
protein phosphatase 2A (PP2A)-binding activity [14]. Instead, a region called the large T stabi-
lization domain (LSD) binds and inhibits diverse E3 ligase recognition proteins including
Fbw7, cdc20 and cdh1 [12, 13]. The latter two proteins are recognition subunits for the ana-
phase promoting complex/cyclosome (APC/C) and sT expression promotes mitotic prometa-
phase arrest [13]. This in turn increases CDK1-directed phosphorylation of 4E-BP1 and
activation of mitosis-associated cap-dependent translation (MACT) [14]. Mutations to the
MCV sT LSD eliminate MCV sT-induced transformation, and knockdown of either LT or sT
initiates cell death or cell cycle arrest of MCV-positive MCC cells [15, 16].
Recently, Spurgeon et al demonstrated that transgenic, keratin 14 promoter-driven MCC-
derived genomic T antigen expression in mouse skin induces papillomatosis [17]. Similarly,
Verhaegen et al demonstrated that transgenic MCV sT expression in mice using a keratin 5
(K5) promoter induces hyperproliferative lesions that mimic human squamous cell carcinoma
in situ [18]. This hyperplasia is dependent on an intact MCV sT LSD region. To date, however,
no mouse models have demonstrated that transgenic MCV T antigen expression induces full
neoplasia.
We generated transgenic mice that conditionally express MCV sT from the ROSA26 locus
to measure the oncogenic potential of this viral protein. We confirm that MCV sT expression
induces a hyperplastic response in skin tissues as previously described. We further demonstrate
that only prolonged MCV sT expression in a p53-null context produces highly anaplastic,
poorly differentiated malignancies in internal organs. This requirement for multiple oncogenic
contributions for full transformation is similar to that seen for c-Myc, Wnt-1 and SV40 LT
[19–21]. We also found that MCV sT induction in Merkel cells of embryonic mice led to tran-
sient increases in Merkel cell numbers but was insufficient to cause proliferation or tumorigen-
esis in adult Merkel cell populations regardless of p53 status.
Results
Generation of MCV sT Transgenic Mouse
A transgenic mouse model with inducible MCV sT expression, ROSAsT, was generated in the
C57BL/6 genetic background. To conditionally express MCV sT protein, codon-optimized
MCV sT (sTco) cDNA was vector cloned downstream of a loxP-flanked neomycin phospho-
transferase cDNA sequence with a 5’ sequence homologous to the mouse ROSA26 locus to gen-
erate ROSA26-CAG-LNL-MCVsTco (Fig 1A). ROSA26-CAG-LNL-MCVsTco was delivered by
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homologous recombination into the ROSA26 locus of mouse embryonic stem (ES) cells (see
details in materials and methods).
High Level Expression of MCV sT in Tissues Is Lethal to Mice
To conditionally induce cre-loxP recombination and sT expression in multiple organs, ROSAsT
mice were mated to UbcCreERT2 mice encoding human ubiquitin C promoter-driven Cre
recombinase fused to a triple mutant form of the human estrogen receptor activatable by
tamoxifen (TMX). We examined sT expression at two different TMX dosing levels: high-dose
TMX activation to promote wide-spread sT expression, and low-dose TMX activation in which
a stochastic fraction of cells in most tissues would undergo recombination and sT expression.
Fig 1. MCV sT expression is lethal in mice. (A) Design of the ROSA26-CAG-LNL-MCVsTco, a ROSA26 knock-in construct encoding codon-optimized
MCV sT with flanking loxP-STOP-Neo-loxP (LNL) sequence, recombined with the ROSA26 genomic locus. ROSA26-CAG-LNL-MCVsTco crossed with
UbcCreERT2 or Atoh1CreERT2mice allows for TMX-induced Cre recombinase excision of the loxP-STOP-Neo-loxP sequence that results in MCV sT expression
under the CAG promoter. (B) MCV sT expression is lethal in UbcCreERT2; ROSAsT transgenic mice. Kaplan-Meier curve of high dose (0.2 mg/g) and low dose
(0.02 mg/g) TMX injected mice. High dose TMX injection caused rapid weight loss and mice reached the euthanasia criterion (20% loss of body weight)
within 5 days of the injection (n = 4, solid orange). Survival of the control UbcCreERT2mice (n = 7, dotted orange) was not affected by TMX injection.
UbcCreERT2; ROSAsTmice injected with lower dose TMX exhibited significantly prolonged survival compared to high dose TMX (n = 18, solid red) and control
mice were unaffected (n = 10, dotted red) (C) Multi-tissue MCV sT protein expression inUbcCreERT2; ROSAsTmice that died immediately after high dose TMX
injection (< 5 days). Lower dose TMX injection induces less MCV sT protein expression in a mouse that died at day 7 after the injection as detected by
immunoblotting using an antibody raised against MCV sT, CM8E6 [22]. MCV sT vector or empty vector transfected HEK293 cells were used as a positive
and a negative control, respectively. Equal amounts of sT-transfected HEK293 cell lysates were loaded for normalization across different blots. Hsp70/Hsc70
was detected as a protein quality control. (D) MCV sT protein expression was maintained in tissues of UbcCreERT2; ROSAsTmice that survived over 70 days
after low dose TMX injection. Immunoblots were performed as in (C). Tissue lysates from ROSAsT were used as a negative control.
doi:10.1371/journal.pone.0142329.g001
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High-dose CreERT2 activation by a single intraperitoneal (i.p.) TMX injection (0.2 mg per
gram of mouse body weight) to adult UbcCreERT2; ROSAsT mice induced rapid weight loss in all
mice tested (n = 4). These mice became dehydrated, less active on day 3 after injection and
reached the 20% weight loss euthanasia endpoint within 5 days. None of the control mice nega-
tive for the UbcCreERT2 transgene showed appreciable weight loss after TMX injection (Fig 1B).
UbcCreERT2; ROSAsTmice did not show weight loss in the absence of TMX injection, and their
survival was comparable to UbcCreERT2 and ROSAsT control mice.
Low-dose TMX, at 10% of the high dose (0.02 mg/g), markedly reduced lethality, with 72%
(13/18) of mice surviving 10 or more days (n = 18) (Figs 1B and 2B) despite a steady weight
loss during the course of the experiment. One such mouse survived 144 days post TMX injec-
tion before reaching the 20% weight loss euthanasia criterion and this was then considered the
endpoint for the study period.
Regardless of the TMX dose, tissue immunoblotting of UbcCreERT2; ROSAsT mice revealed
widespread MCV sT expression in muscle, spleen, lung, liver, kidney, intestine, heart and brain
tissues of mice that died within 10 days after TMX injection whereas low dose TMX induced less
sT protein tissue expression (Fig 1C and S1A Fig). No sT expression was detected in ROSAsT lit-
termate control mice. For mice injected with low-dose TMX and surviving>10 days, however,
MCV sT protein expression in various tissues was reduced compared to those surviving<10
days, with sT protein detected only in ear, skin, muscle and brain tissues by immunoblotting (Fig
1D). MCV sT expression was not detectable except in muscle forUbcCreERT2; ROSAsTmice sacri-
ficed on day 144 post low-dose TMX injection. Increased numbers of TUNEL positive epithelial
cells were detected in the intestine from UbcCreERT2; ROSAsTmice receiving multiple high-dose
TMX (once a day for 3 days), as compared to ROSAsT control mice (S1 Fig). Other organs includ-
ing spleen, lung and kidney showed similar results (data not shown).
Low Dose MCV sT Expression Induces Dermal and Epidermal
Hyperplasia in Ear Tissues
Of the UbcCreERT2; ROSAsT mice that survived over 42 days post TMX injection (n = 12), gross
external examination showed striking bilateral and diffuse thickening of auricles. MCV sT pro-
tein was detected by immunoblotting of ear tissues in 77.8% of mice (7/9, three ear tissues were
not harvested), and sT induction was associated with hyperproliferation of the dermis and epi-
dermis by microscopy in 61.1% (11/18) of UbcCreERT2; ROSAsT mice (Fig 2A). MCV sT protein
expression levels, however, were not associated with this phenotype. Two mice surviving for
over 117 days (9F and 9M) exhibited a hyperplastic ear phenotype despite lack of detectable sT
protein expression in the ears. Neither ROSAsT nor UbcCreERT2 control mice demonstrated this
ear phenotype. Hematoxylin & eosin (H&E) staining of thickened ear tissue showed epithelial
hyperkeratosis (90.9%, 10/11) and hypergranulosis (81.8%, 9/11) (Fig 2). Other than gross and
microscopic ear abnormalities, we detected no other hyperproliferative lesion in this group of
sT-expressing mice.
MCV sT Expression Induces Increased Proliferation in Mouse
Embryonic Fibroblasts
To investigate the dermal fibroblastic proliferation and to determine whether MCV sT affects
cell proliferation in this mouse model, we isolated mouse embryonic fibroblasts (MEFs) from
UbcCreERT2; ROSAsT and ROSAsT embryos. In vitro treatment with 500 nM 4-hydroxy tamoxi-
fen (4-OHTMX) induced MCV sT expression in UbcCreERT2; ROSAsTMEFs (n = 8 embryos)
but not ROSAsTMEFs (n = 2 embryos) (Fig 3A). Some MEFs showed leaky MCV sT expression
even in the absence of 4-OHTMX treatment (S2A Fig). c-Myc expression, which has been
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shown to be stabilized by MCV sT [12], was also increased by MCV sT expression (Fig 3 and
S2B Fig). Wst-1 cell proliferation assay demonstrated that accelerated growth occurred in Ubc-
CreERT2; ROSAsT but not ROSAsTMEFs (Fig 3 and S2B Fig).
Fig 2. MCV sT induces hyperproliferaton of acral skin. (A) Hyperplastic phenotype in ear skin from
UbcCreERT2; ROSAsTmice. Ear skin tissues from UbcCreERT2; ROSAsTmice were subjected to H&E staining.
(B) Hyperproliferative phenotype in ear skin of UbcCreERT2; ROSAsTmice. H&E stained ear skin sections from
low-dose TMX injectedUbcCreERT2; ROSAsT and ROSAsTmice were randomized and evaluated in a blinded
manner by two pathologists for hyperkeratosis/hypergranulosis in the epidermis and increased cellularity/
appendage abnormalities. N/A: not available since ear tissues were normal and not harvested. NT: not
tested.
doi:10.1371/journal.pone.0142329.g002
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MCV sT Expression in p53 Null Mice Produces Anaplastic, Poorly-
Differentiated Neoplasia Expressing Mixed Lineage Markers in Spleen
and Liver
To circumvent the lethality produced by MCV sT expression as reflected by high TUNEL indi-
ces in tissues and rapid death from weight loss of experimental mice, we crossed UbcCreERT2;
ROSAsTmice with p53flox/flox mice to generate UbcCreERT2; ROSAsT; p53flox/flox mice. In these
mice, TMX administration simultaneously induced MCV sT expression and p53 gene deletion.
Fig 3. MCV sT induces hyperproliferaton in MEF cells. (A) Induction of MCV sT in multiple mouse embryonic fibroblast (MEF) cells from littermate by
4-OHTMX. MEFs extracted from UbcCreERT2; ROSAsT and ROSAsT embryos were cultured in the presence or absence of 500 nM 4-OHTMX for 7 days. MCV
sT and c-Myc protein expression was detected by immunoblot. Hsp/Hsc70 protein expression was detected as a loading control. (B) MCV sT expression
accelerates cell proliferation in MEF cells. Proliferation of MEF cells treated with or without 4-OHTMX was evaluated byWst1 assays.
doi:10.1371/journal.pone.0142329.g003
Carcinogenesis in Merkel Cell Polyomavirus Small T Transgenic Mouse
PLOS ONE | DOI:10.1371/journal.pone.0142329 November 6, 2015 6 / 20
Nevertheless, when high dose (0.2 mg/g) TMX was delivered i.p., MCV sT expression was
detected in multiple tissues and all mice died within 5 days (n = 9), suggesting that p53 deletion
does not rescue lethality induced by high levels of sT expression (S3A Fig). As with p53 wild-
type mice, short-term survival rates for UbcCreERT2; ROSAsT; p53flox/flox mice were greater for
low-dose compared to high-dose TMX treated mice (S3A Fig) and 42.3% (11/26) mice died
within 10 days of low dose TMX injection. Widespread MCV sT protein expression was also
detected in multiple tissues from these mice that died within 10 days of low dose TMX injec-
tion (S3B Fig). UbcCreERT2; ROSAsT; p53flox/flox mice also exhibited the hyperkeratosis/hypergra-
nulosis ear skin phenotype seen in p53 wild-type, sT-expressing mice (S4 Fig).
Approximately 19% of UbcCreERT2; ROSAsT; p53flox/flox mice (5/26) survived 60 or more days
post-low-dose TMX treatment (Fig 4A). Four of these five (80%) mice developed high-grade
tumors in internal organs visible at necropsy; three mice had tumors in both the spleen and
liver, and one had grossly detectable tumor nodules in the spleen alone (Fig 4B). By light
microscopy, the tumor cells had highly pleomorphic nuclei that varied dramatically in size and
shape with multiple nucleoli and hyperchromatism. Mitoses were numerous and the cells had
indistinct cytoplasmic boundaries. An immunoblotting survey of tissues (Fig 4C and S5 Fig)
demonstrated that sT was strongly expressed in these tumors whereas sT expression was not
generally detectable in spleens and livers from long-lived UbcCreERT2; ROSAsT mice or the
tumor-negative UbcCreERT2; ROSAsT; p53flox/flox mouse (Fig 1D and S5 Fig). sT protein expres-
sion in splenic tumors was detectable in 75% (3/4) of tumor bearing mice (S5 Fig). sT expres-
sion was also detected by immunoblotting of a representative liver nodule taken from an
affected mouse (p53.7F, Fig 4C). For some of these mice (2/5), MCV sT was also expressed in
kidney tissues and histopathologic examination showed marked proliferative changes in tubu-
lar epithelia ranging from in situ lesions to fully malignant lesions with invasion through base-
ment membranes. Despite microscopic evidence for renal neoplasia, discrete kidney tumors
were not detectable by gross examination at necropsy. Immunohistochemistry showed strong
expression of MCV sT localizing to the malignant lesions from the liver and spleen, and in
hyperproliferative and malignant epithelial lesions of the kidney (Fig 4D). These results were
reproduced at 1/2 low dose TMX (0.01 mg/g) injection. Mouse survival was inversely related to
TMX dosing at 0.01, 0.02, and 0.2 mg/g (S3 Fig). 87.5% (7/8) of UbcCreERT2; ROSAsT; p53flox/flox
mice that survived over 60 days with 0.01 mg/g TMX also developed high grade tumors in
spleen and/or liver tissues (data not shown). We did not observe tumorigenesis by p53 gene
deletion alone in UbcCreERT2; p53flox/flox mice up to 140 days after 0.02 mg/g TMX treatment
(Fig 4A). While germ line deletion of p53 in this mouse model promotes tumor formation as
early as 50 days, it has been shown that postnatal p53 gene deletion leads to a tumor incidence
of only 3% even 600 days after Cre recombinase transduction, indicating that the timing of p53
loss is a critical determinant for tumor incidence [23, 24].
To determine the histogenesis of sT-induced neoplasia, tumors from UbcCreERT2; ROSAsT;
p53flox/flox mice were immunostained with markers for various lineages: CD45 (pan-lympho-
cyte), CD68 (macrophage), α-smooth muscle actin (ASMA-smooth muscle), cytokeratin 14
(epithelial), cytokeratin 8 (epithelial), neural adhesion molecule (NCAM). Tumor cells were
uniformly ASMA positive. Scattered tumor cells showed positivity to CK14 and NCAM (Fig
4E). We saw no staining with the other markers including CD68 and CD45 (S6 Fig).
p53 Ablation Is Required for Full Transformation of MEFs by MCV sT
Given that MCV sT is a transforming oncoprotein in p53-null mice, we performed transforma-
tion assays using isolated MEFs from UbcCreERT2; ROSAsT, UbcCreERT2; ROSAsT; p53flox/flox,
UbcCreERT2; p53flox/flox and ROSAsT mice. Upon 4-OHTMX treatment, clones of MEFs isolated
Carcinogenesis in Merkel Cell Polyomavirus Small T Transgenic Mouse
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Fig 4. MCV sT transgenicmice develop tumors in a p53 null setting. (A) p53 ablation does not rescue mice fromMCV sT-induced lethality. Kaplan-Meier
curve of low dose (0.02 mg/g) TMX injectedUbcCreERT2; ROSAsT; p53flox/floxmice (Solid blue line, n = 26) andUbcCreERT2; p53flox/floxmice (dotted blue line,
n = 10). Pink lines indicate the survival of UbcCreERT2; ROSAsT (solid line) andUbcCreERT2 (dotted line) mice with wild type p53 as shown in Fig 1B for
comparison with p53 knockout background (blue lines). (B) MCV sT expression produces tumors in vivo in p53 null setting. 80% (4/5) of mice that survived
over 60 days after TMX injection develop grossly visible tumor in the spleen and liver. Representative spleen and liver tissues with tumor nodules from
p53.7F are shown with corresponding normal tissues from a C57BL/6 control mouse. (C) Immunoblotting of MCV sT protein expression in liver and spleen
tissues frommouse p53.7F) with macroscopic tumors. Spleen, muscle and ear tissues consistently maintained sT expression over 60 days after TMX
Carcinogenesis in Merkel Cell Polyomavirus Small T Transgenic Mouse
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from two independent UbcCreERT2; ROSAsT; p53flox/flox mice formed colonies 4 weeks after sin-
gle cell seeding in soft agar culture (Fig 5A–5C). Neither MCV sT expression alone (UbcCreERT2;
ROSAsT) nor p53 knockout alone (UbcCreERT2; p53flox/flox) induced colony formation (Fig 6B).
These results are consistent with our in vivo tumorigenesis results.
MCV sT Expression Increases Embryonic Merkel Cell Precursor
Proliferation but Does Not Affect Adult Merkel Cell Numbers or Cause
Tumorigenesis
MCC expresses phenotypic markers most similar to those expressed by normal, resident skin
Merkel cells. To examine the effect of sT in this specific cell type, we targeted sT to Merkel cells
by breeding ROSAsTmice to Atoh1CreERT2/+mice [25]. Atoh1 is an Atonal group proneural basic
helix-loop-helix transcription factor with anti-oncogenic function [26] that plays a critical role in
Merkel cell development [27]. The Atoh1CreERT2/+; ROSAsTmice and control ROSAsT littermates
were given a single dose of tamoxifen (0.25 mg/g) via oral gavage at postnatal day 28 (P28) to
activate sT expression specifically inMerkel cells [28]. Back skin was harvested 7 days or 12
months later and immunostained for the Merkel cell marker keratin 8 (K8). At both time points,
the number of Merkel cells per touch dome was lower in Atoh1CreERT2/+; ROSAsTmice compared
to Atoh1+/+; ROSAsT control mice, consistent with previously reported effects of heterozygosity at
the Atoh1 locus [28] (Fig 6A–6E). At no time did we find touch domes with exceptionally high
Merkel cell numbers, ectopic Merkel cells or evidence of tumor formation. These data suggest
that sT expression alone in adult Merkel cells does not induce cell division or carcinogenesis.
Mitotic Atoh1+ progenitor cells produce mature Merkel cells during late embryogenesis
[28]. To study the effects of sT expression on this population, we administered tamoxifen to
pregnant dams at E14.5 and harvested embryos at E18.5 or at 5 months of age. We found that
E18.5 Atoh1CreERT2/+; ROSAsT mice had ~50% more Merkel cells than littermate controls, while
5 month-old Atoh1CreERT2/+; ROSAsT mice had ~30% fewer Merkel cells than their littermate
controls (Fig 6F–6J). No tumors were found at either age. These data are consistent with sT
expression promoting mitosis in actively dividing cell populations, and demonstrate that touch
dome Merkel cell numbers are regulated even in the face of this increased division. As in adult
animals, MCV sT expression does not transform these cells.
To determine if combined sT expression and loss of p53 would promote Merkel cell prolif-
eration, we administered TMX to E14.5 Atoh1CreERT2/+; ROSAsT; p53flox/flox mice and harvested
skin at P28. We found no increases in Merkel cell numbers and no evidence of tumorigenesis
(Fig 6K–6M). Unlike in sT-induced liver and spleen neoplasia, these data suggest that sT
expression coupled with p53 deletion is insufficient to promote sustained Merkel cell division
or tumorigenesis.
Discussion
MCV sT transforms immortalized rodent fibroblasts such as Rat1 and NIH3T3 [14] and viral
sT expression is required for growth of MCV-positive MCC cancer cell lines [15, 16]. Our
injection. sT expression was detectable in liver tissues by immunoblotting only from liver with visible nodules (mouse p53.7F). MCV sT protein was detected
using CM8E6 antibody, and Hsp/Hsc70 expression was used as a loading control. (D) The top panel shows anaplastic neoplasia in the spleen and liver. A
range of proliferative changes was observed in the kidney, where distal tubular epithelia are most severely affected, but glomeruli (black arrowhead),
proximal tubular epithelia (*), and interstitial tissues are relatively spared of proliferative changes. The middle panel shows a representative
immunohistochemical staining of sT protein expression in liver tumor, spleen tumor and kidney tissues from UbcCreERT2; ROSAsT; p53flox/floxmice. Tissue
samples were immunostained with MCV sT (CM5E1) antibody. (E) The top panel shows a sT-induced liver tumor with immunoreactivity to α-smooth muscle
actin (ASMA) and bottom panel shows K14 positivity in scattered tumor cells.
doi:10.1371/journal.pone.0142329.g004
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current data suggests that MCV expression in the context of p53 loss promotes fully neoplastic
lesions in mice. We find that MCV sT induces embryonic Merkel cell proliferation but is insuf-
ficient to fully recapitulate Merkel cell carcinoma regardless of p53 status.
Recently, Verhaegen et al demonstrated that epithelium-specific sT expression using a K5
promoter in C57BL/6 mice induced hyperplastic lesions resembling squamous cell carcinoma
in situ [18]. This proliferative effect was mediated through the MCV sT LSD domain, which
has been found to target multiple E3 ligase tumor suppressor proteins [12, 13]. In contrast, we
found that ubiquitous postnatal induction of MCV sT expression was uniformly lethal to mice
Fig 5. p53 ablation is critical for MCV sT transformation of MEF cells. (A) MCV sT induces soft agar colony formation in the absence of p53 in MEF cells.
MEF cells isolated form UbcCreERT2; ROSAsT, ROSAsT, UbcCreERT2; p53flox/flox and two UbcCreERT2; ROSAsT; p53flox/flox embryos from littermate were treated
with 500nM 4OHTMX over 7 days, and cells were subjected to soft agar colony formation assay. Asterisks(*) indicate statistical significance p<0.05. (B) Soft
agar colonies induced by p53 ablation. p53 ablation alone did not lead to colony formation. (C) Expression of MCV sT in MEFs from UbcCreERT2; ROSAsT;
p53flox/flox.
doi:10.1371/journal.pone.0142329.g005
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after high-dose TMX injection. Our transgenic mouse model employs a codon-optimized
MCV sT cDNA, which results in higher protein expression than the natural sT cDNA sequence
(data not shown), and cytotoxic effects from increased levels of MCV sT expression may
Fig 6. MCV sT expression increases Merkel cell numbers only during embryogenesis.Wholemount, K8-immunostained skin showing touch domes
from control littermate (A, C, F, H, K), Atoh1CreERT2/+; ROSAsT (B, D, G, I) and Atoh1CreERT2/+; ROSAsT; p53flox/flox (L) mice given TMX at P28 (A-D) or E14.5
(F-I, K, L). Age at tissue harvest is shown for each pair of panels. (E, J, M) Graphs showing Merkel cell counts per touch dome for accompanying panels.
*p < 0.05, ***p<0.001. Scale bar: 10μm.
doi:10.1371/journal.pone.0142329.g006
Carcinogenesis in Merkel Cell Polyomavirus Small T Transgenic Mouse
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account for this difference. Ear, skin, muscle and brain tissues maintained sT expression long
after low-dose TMX injection, suggesting that mice can tolerate chimeric expression of MCV
sT.
Spurgeon et al. also reported that when tumor-derived genomic T antigen (both sT and
MCC-derived truncated LT) is expressed under a constitutive K14 promoter in FVB/N back-
ground mice (K14-MCPyV168), two-thirds of mice are viable, whereas the rest of the mice died
or were euthanized at early age due to malnourishment [17]. We obtained similar results in our
model. HowMCV sT exerts its lethal effects in mouse cells remains unknown. In human
MCC, however, MCV LT may exert a modulatory activity that alleviates MCV sT lethality.
When lower doses of TMX were used to induce sT expression, nearly 70% of UbcCreERT2;
ROSAsTmice survived over 10 days. These mice exhibit a hyperproliferative ear skin pheno-
type, similar to skin hyperplasias described in K5 and K14 tissue specific expression transgenic
mouse models [17, 18]. MCV sT also increased production of Merkel cells in embryonic
Atoh1CreERT2/+; ROSAsTmice. Collectively, these results indicate that sT is a strong growth
accelerator in mouse skin tissue. Despite sT’s proliferative effect, none of the C57BL/6 mice
expressing MCV sT developed fully transformed neoplasia.
Simultaneous induction of MCV sT expression and p53 knockout in C57BL/6 mice, how-
ever, leads to the development of poorly-differentiated neoplasia in the spleen and liver, sug-
gesting the importance of the p53 tumor suppressor pathway in sT-induced tumorigenesis. In
line with these results, sT efficiently induces cell transformation only in the MEFs with p53
deletion. Further, tissues harvested at autopsy from multiple high-dose TMX-treated mice
revealed widespread positivity for apoptosis in intestines, lung, liver and spleen. One explana-
tion for these findings is that sT driven mitogenesis may induce mitotic catastrophe and p53
activation. p53 absence therefore may be protective to cells that would otherwise be eliminated
through a p53-dependent apoptotic response.
This is also consistent with epithelium-specific MCV T antigen transgenic mouse models,
which show activation of the double strand DNA damage marker γH2AX in hyperproliferative
skin epithelium [17, 18]. Oncogene-induced hyperproliferation generally promotes the DNA
damage response (DDR), leading to p53 activation and consequent growth suppression, senes-
cence or apoptosis [29]. Ablation of this anti-oncogenic barrier in early carcinogenesis is criti-
cal for malignant tumor formation [30]. Unlike SV40 LT, however, neither full length MCV LT
nor MCC-derived truncated LT binds to p53 [9, 10], even though a recent study reports that
MCV LT inhibits transcriptional activity of p53 [10]. Because mutations in the p53 gene are
uncommon in MCC tumors [31], upstream or downstream signaling events in the p53 path-
way may be inhibited in MCV-related MCC tumors. sT transformation of immortalized rodent
fibroblast may also be enhanced by sT induced defects in downstream signaling in the p53
pathway, since the p21 gene promoter in Rat1 cells, which can be efficiently transformed by
MCV sT alone, is hypermethylated and does not respond to DNA damage-induced p53 activa-
tion [32]. Although MCV oncogene expression and immune suppression are critical for the
genesis of most MCC tumors [33], no obvious or consistent complementing cellular mutations
have been found for this cancer [34].
In our study, transgenic sT expression was sufficient to promote increased proliferation of
embryonic Atoh1-expressing Merkel cell precursors. However, this effect was short-lived and
did not occur in adult mice, a finding consistent with the majority of adult Merkel cells being
post-mitotic or terminally differentiated. Concomitant deletion of p53 in Atoh1CreERT2/+;
ROSAsT; p53flox/flox mice also failed to promote sustained proliferation or tumorigenesis. It is
possible that LT targeting of RB and RB-related proteins, which has also been shown to be
required for the maintenance of terminal cell differentiation state [35, 36] as well as LT-
induced cell proliferation and MCC cell line survival [9, 11], is a necessary component for
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MCC carcinogenesis. Whether other cellular pathways must also be abrogated to initiate Mer-
kel cell transformation in vivo is unknown.
Alternatively, it is possible that Merkel cell carcinoma does not arise fromMerkel cells, but
rather from another skin lineage. Ectopic expression of Atoh1 in the skin is sufficient to activate
the expression of several Merkel cell markers [37]. If MCV induces cell proliferation of another
skin lineage, and Atoh1 expression is activated either by the virus itself or by complementing
mutations, the resulting tumor cells would express several Merkel cell markers and would
appear to have arisen from the Merkel cell lineage. Further experiments are necessary to test
this hypothesis.
Our results suggest that sT exerts its effects in a variety of organs and tissues. This is evi-
denced by the hyperproliferation seen in vivo not only in the epidermis but also in the dermal
compartment of mouse ears. In support of the latter, in vitro induction of sT in isolated MEFs
from UbcCreERT2; ROSAsT mice showed increased growth compared to ROSAsT controls. In the
p53 null setting, sT-induced neoplasia developed at various internal sites. At least in the kidney,
microscopy coupled with immunohistochemical localization indicates that sT-expressing epi-
thelial cells (CK8 positive) lining renal tubules undergo proliferative changes ranging from in
situ hyperplasia to invasive carcinoma. For the high-grade tumors found in spleen and liver,
the degree of anaplasia exhibited by the tumor cells preclude morphologic classification of
their cell of origin, and immunohistochemical analysis showed co-expression of disparate line-
age markers. ASMA was most consistently expressed in the splenic and hepatic tumors, how-
ever, K14 was also focally expressed. NCAM a neural cell marker was also faintly expressed. In
contrast to proliferative lesions in the kidney, tumors in the spleen and liver were CK8 negative.
Hematopoietic makers were negative in tumors from all sites. It is not uncommon for poorly
differentiated, highly anaplastic tumors to either lose phenotypic markers indicative of origin
or gain anomalous expression of markers due to dysregulation of transcriptional factors. Our
study does not identify the cell of origin in human Merkel cell carcinoma, but clearly supports
the transforming properties of MCV sT in a variety of cell lineages and describes a robust
mouse model for malignant transformation by MCV sT.
Materials and Methods
Ethics Statement
All mice were maintained in accordance with Institutional Animal Care and Use Committee
(IACUC) guidelines at the University of Pittsburgh, and mice experiments were performed
with approval from the Animal Ethics Committee of the University of Pittsburgh (IACUC
breeding protocol #12010072 and IACUC experimental protocols #12020149 and # 13082143).
TMX injections, mice monitoring, and euthanasia were carried out under conditions to mini-
mize pain and suffering in compliance with IACUC guidelines at the University of Pittsburgh
Hillman Cancer Center and the Children’s Hospital of Pittsburgh of the University of Pitts-
burgh Medical Center.
Rosa26 Targeting Vector Construction
Codon-optimized MCV small T (sTco) cDNA was used for the initial ROSA26 targeting vector
construction [14]. The sTco cDNA was isolated from the pcDNA6 vector using HincII and
XhoI restriction endonuclease digestion, which drops out a 571bp fragment. This fragment was
first cloned into G194 vector (Genoway) digested with SmaI and XhoI. The resulting plasmid
was then digested with XhoI and SgrAI to isolate a 585 bp fragment including the sTco cDNA
and hGH polyA, which was cloned into ARC1-pA vector (Genoway) using PshAI and SmaI
restriction sites. The resulting 15648 bp plasmid is called PAM1-HR plasmid and contains
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necessary homology regions and the loxP flanked STOP/neomycin cassette (Fig 1A). Genoway
validated the final targeting vector by restriction analysis as well as sequencing of coding exons.
In addition, sequences of junctions between homology arms and selection cassette as well as
junctions between homology arms and plasmid backbone were confirmed.
Homologous Recombination in ES Cells
40 μg of linearized PAM1-HR targeting plasmid DNA were electroporated into 5x106 C57BL/6
ES cells (260 Volt, 500 μF). ES cells were subjected to 200 μg/mL G418 selection 48 hours after
electroporation. Electroporation was performed 3 times and a total of 1577 clones were isolated
and amplified on gelatin in 96 well plates. The isolated clones were screened for 5’ and 3’
homologous recombination events by PCR and Southern blotting. The correct sTco sequence
was confirmed in 13 out of 15 ES cell clones positive for recombination. 7 ES cell clones were
injected into C57BL/6J-Tyrc-2J/J (C57BL/6 albino strain; white fur color) blastocysts, which
were re-implanted into OF1 pseudo-pregnant females. The resulting chimeric offspring were
screened for the contribution of recombinant ES cells according to their coat color (percentage
of light dark patches was determined). Only one clone from two highly chimeric males with
chimeric rate above 50% was used for breeding to C57BL/6 wildtype females for germ line
transmission. F1 animals were genotyped by PCR using the Phusion high fidelity polymerase
kit (NEB). The F1 generation produced 1 heterozygous male and 2 heterozygous females,
which were bred to each other in order to obtain homozygous animals.
Cross to UbcCreERT2 and AtohCreERT2/+ Mice
To conditionally induce MCV sT expression by cre-loxP recombination in mice, Cre-ERT2
transgenic mice with C57BL/6;129S background (B6;129S-Tg(UbcCreERT2 -/+)1Ejb/J, JAX mice
stock number 007001) or Atoh1CreERT2 transgenic mouse [25] were crossed withMCV sT homo-
zygous transgenic mice (ROSAsT/sT) to generateUbcCreERT2 -/+; ROSAsT/+ or Atoh1CreERT2/+;
ROSAsT/+ C57BL/6 mice. All offspring are heterozygous for the sT transgene (as per Mendelian
genetics), and were genotyped only for theUBCCreERT2 and Atoh1CreERT2 transgenes. The Cre-
ERT2 fusion protein consists of Cre recombinase fused to a triple mutant form of the human
estrogen receptor harboring G400V/M543A/L544A triple mutations of the human estrogen
receptor ligand-binding domain that does not bind its natural ligand. CreERT2 expression is
driven under human Ubiquitin C (Ubc) constitutive promoter (UbcCreERT2) or Atoh1 promoter
(Atoh1CreERT2/+) promoter in mice, and thus TMX injection (0.2 mg/g or 0.02 mg/g for
UbcCreERT2 and 0.25 mg/g for Atoh1CreERT2/+) induces MCV sT protein expression in most tissues
or Atoh1-positive cells including Merkel cells. In Atoh1CreERT2/+mice, the Atoh1 locus is targeted
by a vector replacing its ORF with Cre-ERT2 and neomycin phosphotransferase gene [25].
ROSAsT/+mice and UbcCreERT2 -/+ mice were used as controls and did not induce sT expression
after TMX injection. Mice were monitored daily after TMX injection and euthanized by 100%
carbon dioxide inhalation upon reaching an end-point defined as a constant weight loss reaching
20% of pre-TMX treatment weight, and/or clinical signs consistent with neurological involve-
ment including ataxia, tremors and behavioral changes. No analgesics or anesthetics were used in
the course of the experiment.
To induce p53 knockout and sT expression by TMX treatment, ROSAsT/sT C57BL/6 mice
were crossed to B6.129P2-Trp53tm1Brn (JAX number 008462) that harbors p53 gene exons
2–10 flanked by loxP sites to generate ROSAsT/+; p53flox/flox C57BL/6. UbcCreERT2-/+ C57BL/6
mice were also crossed with p53flox/flox C57BL/6 mice to generate UbcCreERT2-/+; p53flox/flox
C57BL/6 mice. Finally UbcCreERT2-/+; p53flox/flox C57BL/6 mice were crossed to ROSAsT/sT;
p53flox/flox C57BL/6 mice to obtain UbcCreERT2-/+; ROSAsT/+; p53flox/flox from approximately half
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of the littermate. Atoh1CreERT2/+ [25] mice were mated to ROSAST/ST mice to generate Atoh1+/+;
ROSAST/+ and Atoh1CreERT2/+; ROSAST/+ mice in the same litters. ROSAsT/+ mice are indicated
as ROSAsT in the text for simplification. Tamoxifen (0.25 mg/g) was administered by oral
gavage to pregnant dams at E14.5 or adult mice at the specified ages. For embryonic ages, the
plug date was designated as E0.5.
Tissue Processing
Tissues from UbcCreERT2 mice studies were either quickly frozen or fixed in 10% buffered for-
malin (Sigma) for immunohistochemistry. Atoh1+/+; ROSAST and Atoh1CreERT2/+; ROSAST
mice were euthanized by cervical dislocation and back skin dissected into cold PBS. Embryos
were dissected from pregnant dams and decapitated before tissue dissection. Skin processed for
whole-mount immunostaining was fixed in 4% PFA for 30 min (adult tissue or dissected
embryonic skin) then washed in PBS. Some adult skin was embedded in OCT (Thermo Fisher
Scientific), cryosectioned at 20μt 20ectione and counterstained with hematoxylin and eosin
(Sigma-Aldrich).
Genotyping
Genomic DNA was extracted by the NaOH-Tris method. Briefly, 100 μL 50 mMNaOH pH 13
was added to tubes containing ear snips and boiled at 95°C for 15 min. To neutralize the solution,
5 μL of 1.0 M Tris, pH 8.0 was added to the tube. Genomic DNA extracted into the supernatant
was used for PCR. The genotyping PCR reaction forMCV sT contains 2 sets of primers to
amplify the endogenous ROSA26 locus as well as the knock-in allele, which allows for the identi-
fication of wildtype, heterozygous or homozygous genotypes in one PCR run. Primers used to
amplify the endogenous ROSA26 locus are forward primer #4719 (11053-11071(F)) and reverse
primer #4723 (sTco_C-term.F.2). Primers used to amplify the knock-in allele are forward primer
#4656 (027ROSA-PAM1) and reverse primer #4657 (028ROSA-PAM1). The PCR primer sets to
detect Cre-ERT2 are #4666 (genericCre.F) and #4667 (GenericCre.R). Those to detect p53
knock-in allele are #4931 (Trp53tm1Brn.mouse.F) and #4932 (Trp53tm1Brn.mouse.R). The
PCR reaction was performed with an annealing temperature of 58°C for 30 cycles. Primer
sequences and representative sT genotyping results are shown in S7 Fig. The expected product
sizes are ~300 bp for the endogenous Rosa26 locus amplification and ~650 bp for the MCV sT
knock-in allele amplification. Genotyping of offspring from het x het crosses reveals an approxi-
mate adherence to Mendelian genetics.
Immunoblotting and Antibodies
Frozen mouse tissues were placed in separate tubes that were filled with ~1 mL of lysis buffer
(50 mM Tris-HCl pH7.4, 0.15 M NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 2 mM
Na3VO4 and 2 mMNaF) containing protease inhibitors (Complete, Roche). Tissues were
minced in a tube by a surgical scissor on ice, transferred to FastPrep-24 lysing matrix tubes
(MP Biomedicals), and homogenized by FastPrep tissue lyser (FP120/Bio101, Thermo Savant).
Lysates were clarified by centrifugation at 13.2 x 103 rpm for 10 min at 4°C, and supernatant
was collected as soluble protein fraction. Lysates were then resolved by 12% SDS-PAGE and
transferred to nitrocellulose. Membranes were blocked with 5% milk in 1X TBS and incubated
with primary antibodies overnight at 4°C. Blots were subsequently incubated with IRDye-
labeled anti-rabbit or anti-mouse secondary antibodies and analyzed on the Odyssey infrared
scanner (LI-COR Biosciences). The previously described CM8E6 antibody [22] was used to
detect MCV sT. c-Myc protein was detected by rabbit polyclonal antibody c-Myc (C-19)
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(Santa Cruz). A mouse monoclonal antibody to Hsp70 (Santa Cruz) was used to detect Hsp/
Hsc70 as an internal control.
Isolation of Mouse Embryonic Fibroblast Cells
Embryos (ED 13) from UbcCreERT2; ROSAsT (n = 8), UbcCreERT2; ROSAsT; p53flox/flox (n = 2) as
well as UbcCreERT2; p53flox/flox; (n = 1) and ROSAsT (n = 2) were minced and plated individually
in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Most minced
embryos attached to the plate by day 3 after plating. Mouse embryonic fibroblast cells (MEF)
proliferated from minced embryos, were trypsinized and seeded onto culture dishes by day 10
after plating. Cells were trypsinized and seeded into new dishes as first passage MEF cells. To
activate CreERT2, MEF cells were treated with 4OHTMX for 7 days.
Immunohistochemistry
Mouse tissues were fixed with 10% neutral buffered formalin, embedded in paraffin, and 5μm
sections were cut onto glass slides. Immunohistochemistry was performed with primary anti-
bodies to MCV sT (CM5E1, 1:1,000) [14], α-smooth muscle actin (Biocare, CME305A.B,
1:300), CD45 (Millipore, 05–1416,1:300), Keratin14 (Biolegend, PRB-155P, 1:1000), Vimentin
(Santa-cruz, sc-73258,1:300), CK8 (Developmental Studies Hybridoma Bank (DSHB), TRO-
MA-I, 1:20), NCAM (DSHB, AG1, 1:50), and CD68 (Biocarta, CM033B,1:300). Anti-mouse
IgG block are used for mouse primary antibodies, for primary antibodies produced in rat, a
protein blocker (DAKO) was used. MCV sT was immunostained as described previously [14].
For remaining protein targets, 10 mM sodium citrate pH 6.0 buffer was used for heat-antigen
retrieval (Digital Decloaking Chamber, Biocare). Primary antibody was reacted with biotiny-
lated species-specific second antibodies, followed by the avidin-horse radish peroxidase (HRP)
conjugation reaction. HRP activity was visualized using 3-amino-9-ethylcarbazole (AEC) or
3,3’-diaminobenzidine (DAB). Images were captured with an Olympus AX70 microscope
using the Q-Capture Pro7 Program.
Immunofluorescence
For immunofluorescence, body skin was cut into 2mm x 2mm pieces, washed with PBS con-
taining 0.3% Triton X-100 (0.3% PBST) every 30 minutes for 5–8 h, then incubated with rat
anti-keratin 8 (DSHB) diluted 1:20 in 0.3% PBST/5% goat serum/20% DMSO at room temper-
ature for 3–5 days. Samples were then washed with 0.3% PBST every 30 minutes for 5–8 h and
incubated in Cy3-conjugated donkey anti-rat secondary (Jackson ImmunoResearch Laborato-
ries) diluted 1:250 in 0.3% PBST/5% goat serum/20% DMSO at room temperature for 2–4
days. Tissues were washed with 0.3% PBST every 30 minutes for 5–8 h then mounted on slides
with Prolong Gold (Invitrogen).
Cell Counts
Numbers of K8+ cells/touch dome were determined from wholemount, K8-immunostained
skin pieces at least 1 cm2 in size. All K8+ cells in at least 20 touch domes from 2–6 mice per
genotype were counted; no correction factors were applied.
Statistical Analysis
To evaluate statistical significance between two survival curves, the log-rank (Mantel-Cox) test
was performed (PRISM). Statistical comparisons between genotypes in soft agar colonies and
Merkel cell numbers were done using two-tailed t-tests (Excel).
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Supporting Information
S1 Fig. Dose-dependent induction of sT protein expression by TMX and induction of cellu-
lar apoptosis by sT in mice. (A) Quantification of sT protein expression in multiple tissues
from UbcCreERT2; ROSAsT mice surviving<10 days shown in Fig 1C. sT protein expression was
normalized by hsp70 loading control, and relative abundance to equally-loaded control (sT
transfected 293) was determined. Quantification was performed by Li-COR infrared immuno-
blot. (B) Induction of TUNEL positive cells in UbcCreERT2; ROSAsTmice that were sacrificed at
day 3 after multiple high dose TMX treatment (Injected with 0.2 mg/g TMX each day for 3
days).
(PDF)
S2 Fig. MCV sT induces hyperproliferation in MEF cells. (A) MEF cells treated with 500 nM
4OHTMX for 7 days were subjected to sT immunoblots by CM8E6 antibody and c-Myc immu-
noblots. αTubulin was used as a loading control. Littermate 4 and 6 show leaky sT expression
in the absence of 4OHTMX treatment. (B) MCV sT-induced growth acceleration was observed
in multiple MEFs except littermate 4, which showed highest leaky expression. Proliferation of
MEF cells treated with or without 4-OHTMX was evaluated by Wst1 assays.
(PDF)
S3 Fig. p53 ablation does not rescue MCV sT-induced lethality in mice. (A) MCV sT induc-
tion by high dose TMX treatment is lethal regardless of p53 status, and the lethality is TMX
dose-dependent. Kaplan-Meier curve from high dose (0.2 mg/g), low dose (0.02 mg/g) and 1/2
low dose (0.01 mg/g) TMX-injected UbcCreERT2; ROSAsT; p53flox/flox mice. (B) Multi-tissue
MCV sT protein expression in UbcCreERT2; ROSAsT; p53flox/flox mice that died at 8 days after low
dose TMX injection. MCV sT protein expression was detected by CM8E6 immunoblotting.
MCV sT or empty vector transfected 293 cell lysates were used as a positive and a negative con-
trol, respectively. Equal amounts of sT-transfected 293 cells lysates were loaded for normaliza-
tion across different blots.
(PDF)
S4 Fig. Hyperplastic phenotype in ear skin from UbcCreERT2; ROSAsT; p53flox/flox mice. (A)
Representative histology of thickened ear from UbcCreERT2; ROSAsT; p53flox/flox mice (left) and a
control ear from ROSAsT; p53flox/flox mice. (B) A representative H&E-stained section of ear skin
from UbcCreERT2; ROSAsT; p53flox/flox mice.
(PDF)
S5 Fig. MCV sT protein expression in UbcCreERT2; ROSAsT; p53flox/flox mice that survived
over 60 days post TMX injection. sT expression was maintained in 80% of ear skin tissues (4/
5). 75% (3/4) of mice bearing spleen tumors showed sT protein. Except for p53.7F, sT expres-
sion was not detectable in liver tumors because tumors were not macroscopically visible and
could not be excised. MCV sT protein was detected by immunoblot with CM8E6 antibody.
Hsp/Hsc70 expression was used as a loading control.
(PDF)
S6 Fig. sT induced tumors do not originate from macrophages or lymphocytes. sT-induced
liver tumors are negative for CD68 (macrophage marker) and CD45 (lymphocyte marker). sT-
induced liver tumors from p53.7F and control tissues were subjected to immunohistochemical
staining with CD68 and CD45. Normal spleen (UbcCreERT2 for CD68 and UbcCreERT2; p53flox/flox
for CD45) was used as a positive control for each marker staining.
(PDF)
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S7 Fig. Genotyping PCR primers. (A) PCR primers that were used to detect ROSAsT (sT
knock-in allele), ROSAWT alleles, Cre-ERT2, p53floxed allele are shown. (B) Representative
ROSAsT genotyping results for 10 littermates from UbcCre -/+ and ROSAsT+/+ mating. Red arrow
indicates PCR products from ROSAsT (~650bp) while blue arrow from wild type ROSA+ (~300
bp) allele.
(PDF)
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